Anika Therapeutics, Inc. cash flow to debt ratio of 42.62% indicates that the company generates enough cash to cover its debts. This level indicates strong financial health.

Anika Therapeutics, Inc.'s free cash flow has increased -287.13% from $-2.33M last year to $4.36M, signaling increasing performance

Anika Therapeutics, Inc.'s debt to equity ratio is 0.17, which means that the company's assets are healthy financed, signaling financial stability.

Anika Therapeutics, Inc.'s debt has increased relative to shareholder equity from 0.17 last year to 0.17 today, signaling weakened financials

Anika Therapeutics, Inc. has a net cash position, so leverage is healthy.

Interest expense is not separately reported in Anika Therapeutics, Inc.'s latest filing, so interest coverage cannot be calculated.

Anika Therapeutics, Inc.'s profit margin has increased (-93.33%) in the last year from -47.02% to -3.14%, signaling increasing performance

Anika Therapeutics, Inc.'s short-term assets of $103.36M exceed its short-term liabilities of $21.91M

Anika Therapeutics, Inc.'s return on assets of 0.00% is lower than the 5.00% threshold, indicating inefficient asset utilization

Anika Therapeutics, Inc.'s return on equity of -2.70%, is lower than 15.00%, indicating bad performance

Anika Therapeutics, Inc.'s operating cash flow is lower than its net income, indicating that earnings may not be fully backed by cash generation

Anika Therapeutics, Inc. had positive net income in only 1 out of 5 years, indicating unstable earnings

Anika Therapeutics, Inc. has positive free cash flow, indicating the company generates cash after capital expenditures

Anika Therapeutics, Inc. has a free cash flow yield of 1.58%, which is below the 2.00% threshold, indicating limited cash return relative to market value

Anika Therapeutics, Inc.'s yearly earnings has increased -80.70% since last year from $-56.38M to $-10.88M, signaling increasing performance

Anika Therapeutics, Inc.'s yearly revenue has decreased 5.91% since last year from $119.91M to $112.82M, signaling decreasing performance

ROIC -3.17% (Source: FMP key-metrics). Below the 5% partial-credit threshold. Score: 0 of 2. The 5% and 10% cutoffs anchor to typical US weighted-average cost of capital. Below 5% indicates the company is not generating returns above its likely cost of capital under this definition of invested capital. Invested capital here includes equity, non-current liabilities (pension obligations, deferred taxes, lease obligations), and short-term debt. Cash is not subtracted. Companies with substantial float, lease portfolios, or cash holdings will score lower under this definition than under narrower operating-capital definitions. See methodology.

Anika Therapeutics, Inc.'s 3-year revenue CAGR of -0.30% is negative, indicating declining revenue over the past 3 years

Anika Therapeutics, Inc. had revenue growth in only 2 out of 5 years, indicating inconsistent revenue performance

Anika Therapeutics, Inc. had positive ROE in only 1 out of 5 years, indicating inconsistent returns on equity

Anika Therapeutics, Inc. is overvalued relative to its fair value price of 3.92 based on Discounted Cash Flow model

Anika Therapeutics, Inc. has negative trailing-twelve-month earnings; this ratio is not meaningful and the check fails

Anika Therapeutics, Inc. is overvalued relative to its fair value price of 1.42 based on EBITDA multiple model

Anika Therapeutics, Inc. has negative or missing EBITDA, making EV/EBITDA ratio unreliable

Anika Therapeutics, Inc. is overvalued relative to its fair value price of 0.20 based on Earnings Fair Value model

Anika Therapeutics, Inc. has negative trailing-twelve-month earnings; this ratio is not meaningful and the check fails

Anika Therapeutics, Inc. has a price-to-book ratio of 2.02x, which is below the 5.00x threshold, indicating reasonable valuation relative to its book value

Anika Therapeutics, Inc. has a price-to-sales ratio of 2.30x, which is below the 8.00x threshold, indicating reasonable valuation relative to its revenue